July 15, 2009
Standard Drug Courses of Treatment Not Effective for Mesothelioma
Doctors who specialize in cancer treatment choose what type of treatment to prescribe with a patient. The options are endless. There are no universal treatment course for pleural mesothelioma cancer sufferers. This is because of the relative rareness of the disease, the high mortality rate and low treatment success rate, and the few scientific studies to provide meaningful statistics.
The prospects for mesothelioma patients have been grim, but doctors have recently made progress. Traditional treatments for cancer are surgery (removing the tumor and surrounding tissue), chemotherapy (poisoning cancerous cells) and radiation (killing cancer cells with radiation) All three methods have problems. Mesothelioma patients treated with traditional radiation therapy have not responded well to it. Researchers are looking for ways of aiming radiation directly at the tumor in hopes that this will result in less damage to healthy tissue.
The mesothelial tissue around the tumor is removed by surgery. This surgery is extensive and it is not clear how much the patient benefits. Most chemotherapy medication that work on other cancers typically do not work on mesothelioma, and different combinations of chemotherapy drugs have been tried without a lot of success. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
Many advanced techniques in cancer treatment are tried on mesothelioma patients because of its high fatality rate. These techniques include a biologic therapy called the agent interleukin 2 and anti-angiogenesis drugs like thalidomide. Pemetrexed (Alimta) is a new drug that has shown results in extending life.
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Two therapies that are extremely cutting-edge in fighting cancer are called photodynamic and gene therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.











